Registry of patients who received oNKord® treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational registry study enrolls participants who have received at least one dose of oNKord®, which consists of allogeneic ex vivo-generated Natural Killer cells derived from umbilical cord blood. Participants from multiple previous clinical trials of oNKord® can be included, and their treatment history and clinical outcomes will be documented. After signing an informed consent form, participants will be followed for up to three years, with annual assessments of their medical status and any major clinical events. This study aims to gather comprehensive data on the long-term effects of oNKord® treatment in patients with acute myeloid leukemia (AML).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Receipt of at least one dose of oNKord® in a clinical trial
* Participation must be within 3 years after the first infusion of oNKord®
* Signature of ICF

Exclusion Criteria:

* N/A

Where it's running

• Medizinische Hochschule Hannover
  Hanover, Germany Recruiting
• University Hospital Basel
  Basel, Switzerland Recruiting

Study contacts

• Study coordinator: Katarzyna Nowek, PhD
• Email: medical@glycostem.com
• Phone: +31(0)412211001

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 6MW5311 in adults with relapsed or refractory blood cancers

  This study tests increasing doses of 6MW5311 in adults with multiple myeloma, AML, or CMML to see if it is safe and tolerable and to find a suitable dose for later studies.

  Recruiting Phase 1 Mabwell (Shanghai) Bioscience Co., Ltd. · Shanghai, Shanghai Municipality · NCT07914556

• CRD3874-SI in People with Leukemia

  A small early-stage study tests CRD3874-SI to see if it is safe for adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07661095

• Allogeneic CAR-T CT0890B for relapsed/refractory AML

  This study tests whether a universal CAR-T cell therapy called CT0890B is safe and potentially effective for adults with relapsed or refractory acute myeloid leukemia who express NKG2D ligands.

  Recruiting Phase 1 Peking University People's Hospital · Beijing · NCT07617285

• Biomarkers in Bone Marrow to Predict AML Chemosensitivity

  This study tests whether markers in bone marrow can predict how adults with AML will respond to chemotherapy.

  Recruiting Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT07587944

• Azacitidine plus venetoclax maintenance vs azacitidine alone in AML

  This trial tests whether adding venetoclax to azacitidine maintenance helps people with AML stay disease-free after achieving first remission.

  Recruiting Phase 3 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07539818

• Azacitidine with APG1252 in high-risk AML (Phase 1b/2)

  This study tests whether adding APG1252 to azacitidine is safe and helps some patients with high-risk AML feel better or respond to treatment.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07508982

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.